Mitomycin Patent Expiration
Mitomycin was first introduced by Bristol Laboratories Inc Div Bristol Myers Co
Mitomycin Patents
Given below is the list of patents protecting Mitomycin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jelmyto | US12268745 | Material and method for treating internal cavities | Jan 20, 2031 | Urogen Pharma |
| Jelmyto | US9040074 | Material and method for treating internal cavities | Jan 20, 2031 | Urogen Pharma |
| Jelmyto | US9950069 | Material and method for treating internal cavities | Jan 20, 2031 | Urogen Pharma |
| Zusduri | US10039832 | Material And Method For Treating Internal Cavities | Jan 20, 2031 | Urogen Pharma |
| Zusduri | US12440568 | Material And Method For Treating Internal Cavities | Jan 20, 2031 | Urogen Pharma |
| Zusduri | US9040074 | Material and method for treating internal cavities | Jan 20, 2031 | Urogen Pharma |
| Zusduri | US9950069 | Material and method for treating internal cavities | Jan 20, 2031 | Urogen Pharma |
| Mitosol | US9649428 | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application | May 21, 2029 | Glaukos |
| Mitosol | US7806265 | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application | Feb 01, 2029 | Glaukos |
| Mitosol | US9539241 | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application | Jan 02, 2028 | Glaukos |
| Mitosol | US8186511 | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul 19, 2026
(Expired) | Glaukos |
| Mitosol | US9205075 | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul 19, 2026
(Expired) | Glaukos |
Mitomycin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Mitomycin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
